Search
Kura Oncology Inc
KURAAdd to Watchlist
11.890USD
+0.180+1.54%
Close 08-21 16:00（ET）
1.06BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-21The current earnings forecast score of Kura Oncology Inc is 8.25, ranking 147 out of 377 in the Biotechnology & Medical Research industry. The average price target is 28.00, with a high of 76.00 and a low of 16.00.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
32.727
Target Price
+179.48%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Kura Oncology Inc
KURA
16
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Kura Oncology Inc's expected revenue for the next quarter?
Kura Oncology Inc's expected revenue is 24.66M.
What is Kura Oncology Inc's price target?
Analysts forecast that Kura Oncology Inc's price target is USD 28.00, with the highest forecast at USD 76.00 and the lowest forecast at USD 16.00.
How have Kura Oncology IncKURA's recent earnings per share performed?
The market expectation was USD -0.77, while Kura Oncology IncKURA's earnings per share (EPS) for the previous quarter was USD -0.83. EPS for the next quarter is expected at USD -0.83.
What is the analyst rating for Kura Oncology Inc?
Based on the ratings of Kura Oncology Inc's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.